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fractions for 5 days a week. Toxicity was recorded using the 
CTCAE v4.0 to define a Dose Limiting Toxicity (DLT) and a 
Maximum Tolerated Dose (MTD) of MTL005. 
 
Results: A total of 8 patients, 7 males (88%) and 1 female 
(12%), were enrolled, 4 in each of the 2 dose level cohorts. 
Six patients, all male with median age of 65 (54-77), were 
dosed with MTL005 successfully, 3 in each cohort. Dosing 
failures were due to an unexpected severe pain reaction (1 
patient) and a technical problem with the infusion line (1 
patient). In the 6 evaluable patients the following adverse 
events were recorded. Grade ≤2 oral mucositis and dysphagia 
were recorded in 3 (50%) and 4 (67%) patients respectively. 
Grade 1 pain in site of MTL005 injection was assessed in 1 
(17%) patient. Grade ≤2 other toxicities (anaemia, dysgeusia) 
occurred in 3 (50%) patients. Grade 3 (dyspnoea, 
pneumonitis, oral haemorrhage, back pain, hyperuricemia) 
and Grade 4 toxicity (sepsis) were recorded in 4 (67%) and 1 
(17%) cases respectively requiring hospitalisation and being 
considered as Serious Adverse Events (SAE). None of the SAE 
was assessed as directly related to MTL005 so DLT/MTD was 
not defined. 
 
Conclusion: We completed Part 1 of the study and MTL005 
DLT/MTD was not defined. Part 2 has been commenced with 
a MTL005 starting dose of 4mg/kg and is currently ongoing. 
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Purpose or Objective: To assess the prognostic role of 18F -
FDG PET/CT based response evaluation after primary 
concomitant radio-chemotherapy (RCT) for loco regionally 
advanced Head and Neck squamous cell carcinoma (HNSCC). 
 
Material and Methods: 150 patients were included in this 
retrospective study. Mean age was 59 years (107 males and 
43 females). The sites of HNSCC were oropharynx (53%), 
nasopharynx (14%), oral cavity (10%), hypopharynx (7%), 
larynx (7%), salivary glands (5%) and paranasal sinuses (4%). 
All patients underwent 18F-FDG PET/CT between 2006 and 
2013 to assess treatment response; 62% of patients also had a 
pre-therapy 18F -FDG PET/CT scan. 18F -FDG PET/CT was 
performed from 6 to 36 weeks (median 21 weeks) after the 
end of RCT. Patients were divided in three groups: 18F -FDG 
PET/CT performed from 6 to 14 weeks after the end of RCT 
(group I: 30 patients), from 15 to 23 weeks (group II: 89 
patients) and from 24 to 36 weeks (group III: 31 patients). 
18F -FDG PET/CT scans were performed according to 
standard procedure, then they were visually analysed by 2 
expert physicians and categorized as negative (“score 1”), 
doubt negative (“score 2”), doubt positive (“score 3”) and 
positive (“score 4”). Patients were followed-up, based on 
clinic and radiological and/or histological findings. Median 
follow up was 38 months (range, 12-60 months). At the end 
of the follow-up 18F-FDG PET/CT were classified as true 
positive (TP), true negative (TN), false positive (FP) and false 
negative (FN). 
 
Results: Group I showed “score 1” in 14 patients, “score 4” 
in 11 patients and therefore 18F-FDG PET/CT sensitivity was 
69%, specificity 83%, VPP 82%, VPN 72%, and accuracy 0.76. 
This group showed 5 doubt scans (16%) as “score 2” that were 
find out to be 2 negatives and 3 positives. No “score 3” was 
observed in this group. Group II showed “score 1” in 55 
patients, “score 4” in 27 patients and therefore 18F-FDG 
PET/CT sensitivity was 87%, specificity 98%, VPP 96%, VPN 
93%, and accuracy 0.94. This group showed 7 (8%) doubt 
scans: 3 scans (3.5%) as “score 2” that in follow-up were 1 
negative and 2 positives and 4 scans (4.5%) as “score 3” that 
were found out to be 2 negatives and 2 positives. Group III 
showed “score 1” in 24 patients and “score 4” in 6 patients 
and therefore 18F-FDG PET/CT sensitivity was 86%, 
specificity 100%, VPP 100%, VPN 96%, and accuracy 0.97. This 
group showed only 1 doubt scan (3%) as “score 2” that was 
find out to be negative. 
 
Conclusion: According to our data, PET/CT with 18F-FDG 
showed an excellent prognostic value of treatment response 
to primary concomitant RCT if performed at least 14 weeks 
after the end of RCT. We also observed that the numbers of 
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Purpose or Objective: The role of post-operative external 
beam radiotherapy (EBRT) in differentiated thyroid 
carcinomas is still discussed considering the low clinical 
aggressiveness and the possibility to perform a radioiodine 
ablation (RAI). However, there are dedifferentiated tumors 
that, over time, lose their capacity to capture Iodine. The 
aim of this study is to evaluate the utility of 18F-FDG PET/CT 
in volumes defining and the clinical response rate after EBRT 
in these patients. 
 
Material and Methods: Patients with locally recurrent thyroid 
cancer, treated with radical EBRT from October 2011 to 
March 2015 after total thyroidectomy and RAI, were included 
in the study. When EBRT was planned, thyroglobulin (HTG) 
was detectable and there was negative post-RAI whole body 
scintigraphy (WBS) and no surgical indications. All patients 
underwent a pre-treatment 18F-FDG PET/CT that resulted 
positive: 3 in loggia, 3 in loggia and lymph nodes, 9 in lymph 
nodes, 1 in lymph nodes and in lung. EBRT was delivered with 
IMRT-SIB technique: a dose of 66 Gy (2.2 Gy/fr) to increased 
FDG-uptake areas, 60 Gy (2 Gy/fr) to ipsilateral lymph nodes 
and 54 Gy (1.8 Gy/fr) to contralateral ones, in 30 fractions, 1 
fr/die. A revaluation 18F-FDG PET/CT and HTG dosage during 
the follow-up (range: 5-43 months) was performed. Acute 
and late toxicity were assessed with CTCAE v. 4.03 and 
EORTC-RTOG scales respectively, the metabolic, clinical and 
instrumental response with PERCIST and RECIST criteria. 
Local control (LC) and overall survival (OS) were analysed 
with Kaplan-Meier method. 
 
Results: Sixteen patients were treated and analyzed 
consecutively [M / F: 8/8; median age: 71 years; range: 36-
81; histology: 15 papillary carcinomas and 1 follicular 
carcinoma; UICC stage: III-IV]. Post-EBRT 18F-FDG PET/CT 
showed CR in 7 (43.8%), PR in 5 (31.2%), SD in 4 (25.0%) 
patients and unknown lung metastases in 2 patients (12.5%). 
HTG decreased in agreement with PET/CT results. 4 patients 
(25.0%) had G3 skin acute toxicity and no one showed G4 late 
toxicity. LC and OS rates were 100% at last follow-up (median 
F-UP: 12.3 months). 
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Conclusion: 18F-FDG PET/CT is useful to target volumes 
delineation for radiotherapy planning, allowing a clear 
definition of GTV, not detected with 131I WBS. Disease 
response and local control justify future prospective studies. 
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Purpose or Objective: To evaluate long-term results, 
prognostic factors, quality of life (QoL) and voice and thyroid 
toxicity and risk of second tumors in T1N0M0 glottic 
carcinoma. 
 
Material and Methods: A total of 100 patients with stage 
T1N0M0 histologically proven squamous cell glottic carcinoma 
treated between 2000 and 2012 were retrospectively 
analyzed. Mean age: 62.14 years; 90 males, 10 female; stage: 
T1a:80, T1b:20. Treatment: radical external radiotherapy 
with a mean dose of 70 Gy (2Gy/fraction). Statistical 
analysis: Kaplan-Meier method and Chi-square test. In 35 
patients, we prospectively evaluated the Voice Handicap 
Index (VHI 30) and the QoL with (EORTC)–QLQ C30 
questionnaire and organ-specific EORTC-Head & Neck-35 
module. In the functional and QoL scales of the QLQ C30 
questionnaire a higher score represent better functioning and 
quality of life, whereas in symptoms scales of both 
questionnaires a high score implies a higher level of 
symptoms. The last two questions in QLQ C30 represents a 
QoL scale ranging from 1 (“very poor”) to 7 (“excellent”). 
Blood determination of TSH, T4, T3 levels was performed in 
19 patients. Second primary tumors were defined as those 
originated outside the head and neck area. 
 
Results: Median follow-up: 91.5 months. Five-and 10-year 
actuarial OS and disease free survival were 83% and 70%, and 
70% and 57% respectively. Five- and 10-year actuarial LC and 
metastasis free survival were 84% and 77%, and 97% and 94% 
respectively. Eighteen patients had recurrent disease. Mean 
time to local recurrence was 80 months. Sex, stage, grade 
and Overall Treatment Time were not statistically significant 
prognostic factors. Mean score (MS) for the VHI30 was 19.16, 
which is considered as a minimal amount of voice handicap. 
Patients reported excellent QoL in the C30 questionnaire 
which showed functional scores above 93 and symptoms 
scores below 14. The global health status and QoL scale were 
5.93 and 6, respectively, which should be considered as 
“good” or “very good”. In the H&N 35 questionnaire the 
worse scores were dry mouth and thick saliva (MS 30.6 for 
both). Most patients have no problems in open mouth, 
swallowing, speaking and social contact (MS of 0, 6.9, 18.6 
and 16.6, respectively). There were no patients with clinical 
or subclinical hypothyroidism. Mean TSH, T3, and T4 were 
2.32, 3.16 and 1.31, respectively. Mean TSH was not 
statistically different from normal values (P: 0.34) Eighteen 
patients (18%) had second tumors: 11 lungs, 2 prostates, 5 
others. Ten years probability of second lung cancer was 28%. 
 
Conclusion: In our series radical radiotherapy for T1 glottic 
cancer was well tolerated and achieved excellent tumor 
control comparable to surgery. In our opinion radical 
radiotherapy should be the standard treatment of these 
patients given the excellent results in QoL and voice 
preservation. The high probability of second lung cancer 
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Purpose or Objective: We investigated the treatment 
outcome of induction bio-chemotherapy followed by IMRT for 
advanced nasopharyngeal carcinoma (NPC) and the 
prognostic impact of plasma EBV DNA viral load. 
 
Material and Methods: Forty-two NPC patients with 
previously untreated, stage III/IV received induction 
chemotherapy of weekly P-FL (cisplatin 60 mg/m2 d1, [5-
fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2] d8) ± 
docetaxel 50 mg/m2 or gemcitabine 1000 mg/m2 d15, for 10-
12 weeks and concurrent Cetuximab 400 mg/m2 day 1, then 
weekly 250 mg/m2. Conventional (70 Gy/35fr) or 
hyperfractionated (76.4 Gy/64fr for T4 tumor) RT were 
delivered by IMRT technique. Plasma EBV DNA levels were 
measured before, during and after treatment regularly. 
 
Results: Baseline characteristics are median age=44; 
male/female=28/14; performance status ECOG 0/1=13/12; 
stage III/IV=22/20, and pathological type (WHO) 
IIa/IIb=20/22. Each patient received a mean of 11 weekly 
cetuximab. During induction bio-chemotherapy period, 
cetuximb-associated toxicity included 100% skin rashes (grade 
50% III/IV), 64.3% (27/42) dry skin, 52.4% (22/42) paronychia, 
and 28.6% (12/42) hypomagnesia. Grade III/IV conventional 
toxicities were rare (11.9% leucopenia, 9.5% anemia, 2.4% 
thrombocytopenia, and 2.4% mucositis). Response after 
induction bio-chemotherapy revealed 50% CR and 50% PR. 
After a median follow-up of 24 months, there were 1 local, 1 
regional, and 5 distant failures. The 3-year local failure-free, 
neck failure-free, distant metastasis failure-free (DMFS), 
progression-free survival (PFS), and overall survivals (OS) 
were 96.6%, 96.0%, 87.4%, 79.9%, and 92.1% respectively. 
Patients with high pretreatment plasma EBV DNA predict 
significantly lower PFS and DMFS (P=0.0108 and P=0.004) but 
not OS (P=0.6291). Patients with detectable plasma EBV DNA 
after bio-chemotherapy had a significantly lower OS, PFS, 
and DMFS (P=0.0294, P=0.0078, and P=0.0082). Patients with 
persistently detectable plasma EBV DNA one week after IMRT 
predict a significantly lower PFS (P=0.0258). 
 
Conclusion: Induction Bio-chemotherapy followed by IMRT is 
a highly effective protocol with very low toxicity in advanced 
NPC. Plasma EBV DNA monitoring are the most important 
prognostic factors in outcome prediction. 
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Purpose or Objective: The choice of fractionation scheme in 
radiotherapy of head and neck cancer (HNC) is still debated. 
In fact it is well known that a shorter overall treatment time 
and a dose escalation, may improve loco-regional control of 
disease by reducing cell repopulation. Nevertheless, 
shortening overall treatment time can result in worse acute 
toxicity.Volumetric modulated arc therapy (VMAT) with 
Simultaneous Integrated Boost (SIB), allowing 
hypofractionation with a better sparing of the organs at risk, 
has showed promising results in terms of outcome and 
pattern of toxicity.In this study we retrospectively analyzed a 
series of patients with stage III-IV HNC treated with VMAT-SIB 
